OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: A randomized phase III trial

Cancer

Volumn 83, Issue 10, 1998, Pages 2054-2059

  Kim, Si Young ^a,b   Park, Ho C ^a   Yoon, Choong ^a   Yoon, Hwi J ^a   Choi, Yong M ^a   Cho, Kyung S ^a  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University College of Medicine   (South Korea)

Author keywords

5 flourouracil; Doxorubicin; FAM regimen; Gastric carcinoma; Mitomycin C; OK 432

Indexed keywords

DOXORUBICIN; FLUOROURACIL; MITOMYCIN C; PARACETAMOL; PICIBANIL;

ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MITOMYCIN; PICIBANIL; STOMACH NEOPLASMS;

EID: 0032533628     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981115)83:10<2054::AID-CNCR2>3.0.CO;2-1     Document Type: Article

References (18)

1. Okamoto H, Xhoin S, Koshimura S, Shimizu R. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 1967;11:323-36.
2. Ono T, Kurata S, Wakabayashi K, Sugawara Y, Saito M, Ogawa H. Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumor cells in vitro. Gann 1973;64:59-69.
3. Sakurai Y, Tsukagoshi S, Satoh H, Akiba T, Suzuki S, Takagaki Y. Tumor-inhibitory effect of a streptococcal preparation (NSC-B116209). Cancer Chemother Rep 1972;56:9-17.
4. Kimura I, Ohnoshi Y, Yasuhara S, Watanabe T, Sugiyama M, Kiraki K. Studies on the host-mediated action of the streptococcal preparation, OK-432, in cancer chemotherapy. Acta Med Okayama 1974;28:423-31.
5. Ishii Y, Yamaoka H, Toh K, Kikuchi K. Inhibition of tumor growth in vivo and in vitro by macrophages from rats treated with a streptococcal preparation, OK-432. Gann 1976;67:115-9.
6. Oshimi K, Kano S, Takaku F, Okumura K. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst 1980;65:1265-9.
7. Oshimi K, Wakasugi H, Seki H, Kano S. Streptococcal preparation OK-432 augments cytotoxic activity against an erythroleukemic cell line in humans. Cancer Immunol Immunother 1980;9:187-92.
8. Matsubara S, Suzuki F, Ishida N. Induction of immune interferon in mice treated with a bacterial immunopotentiator, OK-432. Cancer Immunol Immunother 1979;6:41-5.
9. Sato M, Yoshida H, Yanagawa T, Yura Y, Urata M, Atsumi M, et al. Effects of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer. Int J Oral Surg 1984;13:7-15.
10. Misaki T, Watanabe Y, Iida Y, Hidaka A, Kasagi K, Fukushima H, et al. Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy. Cancer Immunol Immunother 1992;35:92-6.
11. Watanabe Y, Iwa T. Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer 1984;53(2):248-53.
12. Torisu M, Katano M, Kimura Y, Itoh H, Takesue I. New approach to management of malignant ascites with a streptococcal preparation OK-432: I. Improvement of host immunity and prolongation of survival. Surgery 1983;93:357-64.
13. Kimura T, Suzuki K, Motai H, Miyamoto N, Tsuge I, Ito Y, et al. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immuno-potentiator for laryngeal cancer. Acta Otolaryngol (Stockh) 1996;525(Suppl):135-41.
14. Mukai M, Ryu M, Kikuchi T. Preoperative combination therapy involving local administration of a non-specific immunoactivated preparation (OK-432) and chemotherapeutic preparation for patients with stomach cancer. Gan To Kagaku Ryoho 1985;12:880-6.
15. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-202.
16. Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-7.
17. Tanaka N, Gouchi A, Ohara T, Mannami T, Konaga E, Fuchimoto S, et al. Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. Cancer 1994;74:3097-103.
18. Kim J-P, Kwon OJ, Oh ST, Yang HK. Results of surgery on 6,589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 1992;216:269-79.